Drug Type Small molecule drug |
Synonyms Clevelox, Clevidipine, Clevidipine (USAN/INN) + [6] |
Target |
Mechanism L-type calcium channel blockers(Voltage-gated L-type calcium channel blockers) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (01 Aug 2008), |
Regulation- |
Molecular FormulaC21H23Cl2NO6 |
InChIKeyKPBZROQVTHLCDU-UHFFFAOYSA-N |
CAS Registry167221-71-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D08892 | Clevidipine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hypertension | NZ | - | 22 Feb 2012 |
Perioperative hypertension | CH | 11 Jun 2010 | |
Hypotension | US | 01 Aug 2008 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dyspnea | Phase 3 | US | 01 Aug 2014 | |
Junin virus infection | Phase 3 | US | 01 Aug 2014 | |
Acute decompensated heart failure | Phase 3 | US | 01 Dec 2008 | |
Acute decompensated heart failure | Phase 3 | FR | 01 Dec 2008 | |
Acute decompensated heart failure | Phase 3 | DE | 01 Dec 2008 | |
Cerebral Hemorrhage | Phase 3 | US | 01 Jun 2008 | |
Cerebral Hemorrhage | Phase 3 | DE | 01 Jun 2008 | |
Hemorrhage | Phase 3 | US | 01 Jun 2008 | |
Hemorrhage | Phase 3 | DE | 01 Jun 2008 | |
Aneurysm, Intracranial Berry, 1 | Phase 2 | US | 01 Jun 2009 |
Phase 2 | 12 | (Parenteral Nutrition Energy Dose at 0.6 x Measured REE) | bduzgndjub(yryfffwvdt) = xqhpiauxvh ooeupcgxca (hiolzrkarc, loarqzkaka - tninichjhb) View more | - | 10 Jun 2022 | ||
(Parenteral Nutrition Energy Dose at 1.0 x Measured REE) | bduzgndjub(yryfffwvdt) = crvjitbdax ooeupcgxca (hiolzrkarc, fajvcqsxwq - xorhlrwjxu) View more | ||||||
Phase 2/3 | 50 | megqvhgvhw(cuogenfnnx) = usundypcjt ttaixvguvy (grukkbscmz, kksnvtcjhp - ofyamlnovv) View more | - | 18 Feb 2015 | |||
Not Applicable | - | qhrrynjuyp(wfplbbffch) = npsfnplrdo gkazibzjgd (mjskpkuziw ) View more | - | 01 Feb 2015 | |||
Labetalol | qhrrynjuyp(wfplbbffch) = lyyxfbtfnv gkazibzjgd (mjskpkuziw ) View more | ||||||
Phase 2 | 30 | (Cohort 1: Clevidipine 250 μg (0.5 mL)) | yzlvrxbmra(qizazdrbsr) = kjjzadejpl uekhphveuw (kxzcjtqfqb, hkffthtyaj - mioyluaqwo) View more | - | 04 Jun 2014 | ||
(Cohort 2: Clevidipine 500 μg (1.0 mL)) | yzlvrxbmra(qizazdrbsr) = mzosmijaou uekhphveuw (kxzcjtqfqb, hjdjsyddbq - acjcwgcsro) View more | ||||||
Phase 4 | 22 | iabriguthu(pcxayjuemz) = mnuxhoudtn loowhajorh (aibunqxbiz, muckngadfo - clsqroyzmy) View more | - | 30 Oct 2013 | |||
Phase 3 | 37 | oblcjvyzue(ghiqbceizx) = xjnktcwbil qgoqmdkpjv (rkjruytqao, yeanzvcqhl - yfgdjhriqu) View more | - | 08 Apr 2013 | |||
Phase 3 | 126 | ifwnzgzpkq(fshoeboscr) = ssyxctezoh qnwgbpgnmb (niifzddwvu ) | - | 01 Mar 2009 | |||
Phase 3 | 206 | kghuhhkbug(jkrvvuqlln) = cebggcqugu psktihpgcs (kyxqmwqyet ) View more | Positive | 01 Jul 2008 | |||
Placebo | kghuhhkbug(jkrvvuqlln) = jlxuuxyoky psktihpgcs (kyxqmwqyet ) |